Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833690 · ClinicalTrials.gov registry record · Phase 2
Safety of Urate Elevation in Parkinson's Disease
A Phase 2 study, sponsored by The Parkinson Study Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00833690: Completed Phase 2 study, sponsored by The Parkinson Study Group.
NCT00833690 is a Phase 2 study that has completed, run by The Parkinson Study Group. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833690, a Phase 2 study, has completed, sponsored by The Parkinson Study Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease. This will determine whether it is appropriate to proceed with a larger study of inosine's ability to modify the rate of disability progression in PD.
Primary Outcome
Defined as the extent to which assigned treatment could continue without prolonged dose reduction (\>48 consecutive days or \>73 cumulative days, which is 10% of total 2-year follow-up) due to adverse experiences (AEs), and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).
Interventions
- DRUG Placebo
- DRUG inosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00833690 record still lists
NCT00833690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00833690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00833690 about?
NCT00833690 is a clinical study titled "Safety of Urate Elevation in Parkinson's Disease". The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease. This will determine whether it is appropriate to proceed with a larger study of inosine's ability to ...
What is the current status of trial NCT00833690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2009-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00833690?
The interventions under investigation include: Placebo (DRUG), inosine (DRUG).
Who is sponsoring clinical trial NCT00833690?
This trial is sponsored by The Parkinson Study Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00833690's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia